DrugDashboards

Victoza

liraglutide · LIRAGLUTIDE 6 mg/mL · Injection · Subcutaneous · Novo Nordisk

NDC 00169-4060-99 · 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC · NDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “delay in shipping of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00143-9144-03) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$58.47per unit
middle half $38.03–$65.92 · 834 plans · Apr 1, 2026
Est. net of rebatesⓘ
$35.08–$43.85
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
15%of plans cover it
tier 3 · prior auth 100% · step therapy 0% · qty limit 86%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 6 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.3%chance of a new FDA shortage posting for liraglutide (injectable) in the next 90 days

sterile injectable · sole-source market · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $935.05 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA022341
TE code
AP1
Approval date
Jan 25, 2010
Patents / exclusivity
4 patents, 0 exclusivities
TypeNumber / codeExpires
patent9968659*PEDJul 9, 2037
patent9968659Jan 9, 2037
patent8114833*PEDFeb 13, 2026
patent8114833Aug 13, 2025

Shortage history

  • In shortage now — Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)Jul 18, 2023
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)Jul 18, 2023
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)Jul 18, 2023
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)Jul 18, 2023
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)Jul 18, 2023
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)Jul 18, 2023
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)Jul 18, 2023
    Delay in shipping of the drug
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months
  • In shortage now — Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)Jul 18, 2023
    Delay in shipping of the drug
    month 38 of a typical 20 for injectable shortages · model puts 33% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · TerminatedMar 22, 2021
    Novo Nordisk Inc — Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Manufacturers of liraglutide (Injection)

LabelerStrengthFirst seenLast seen
Biocon Pharma Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
NorthStar Rx LLCLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Novo NordiskLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsLIRAGLUTIDE 6 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Victoza — NDC 00169-4060-99," retrieved September 3, 2026, https://drugdashboards.com/drug/00169406099.

Free to cite with attribution — see how the data is put together.